Congratulations to the 2021 Research Grant winners!


The Hague, 2 June 2021 –EHA congratulates nine talented researchers in hematology on their receipt of the EHA Research Grants 2021 after a rigorous selection process.

Read more

EHA Issues Recommendations on Mild to Moderate Bleeding Disorders

HemaSphere website block2

HemaSphere presents first in a series of Consensus Reports on Diagnosis of Inherited Bleeding Problems

Read more

Hematology in the spotlight at EAPM Presidency Conference

EAPM image

April 9, Brussels - The European Alliance for Personalised Medicine is holding its 7th annual presidency conference at the University Foundation in Brussels, and the event will include a session...

Read more

Michel Boiron 1925-2018

It is with great sadness that we announce the passing of Professor Michel Boiron last December 3. Boiron was the founding President (1992-1994) of the European Hematology Association (EHA).

Read more

First CMML guidelines produced by EHA, now available

EHA 03

Joint recommendations on diagnosis and treatment of CMML from two European specialty societies were published the December issue in HemaSphere, the official journal of the European Hematology Association (EHA).

Read more

EHA and EBMT joint meeting on CAR T cells, first of its kind in Europe

Mailing Headers EHA EBMT CAR T Cell Meeting 16

The European Hematology Association (EHA) and European Society for Blood and Marrow Transplantation (EBMT) will hold the first European CAR T Cell Meeting together in Paris on February 14-16, 2019.

Read more

EHA-funded study in The Lancet Haematology: Economic Burden of Blood Disorders i...


Two studies funded by EHA and published in the medical journal Lancet Haematology by a team of researchers from Oxford University and King’s College found that the economic burden of blood disorders (malignant and non-malignant) across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more

Press Release: Economic burden of blood disorders in EU is €23 billion

AdobeStock 71232722

The economic burden of blood disorders across the European Union, Iceland, Norway and Switzerland amounts to €23 billion per year.

Read more

SGN-CD33A Combined with Hypomethylating Therapy Produces High Remission Rates am...

Acute myeloid leukemia (AML) is an aggressive form of blood cancer in which the majority of cases express CD33 on the surface of the leukemia cells.

Read more

Killer antibodies against AML

Most patients with acute myeloid leukemia (AML) can only be cured when a stem cell transplant induces an immune response against the patient’s leukemia.

Read more

Improved survival for adult Acute Lymphoblastic Leukemia (ALL) patients

Historical survival for patients 18-45 years with ALL is approximately 40 %. However the event free survival for ALL patients 18-45 years has improved to 73% following implementation of the...

Read more

The Clot Thickens

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Read more

Genome sequencing of thousands of patients with rare blood disorders

Approximately 3M people have a rare bleeding disorder or disease of platelets, which are the cell fragments that help blood clot.

Read more

Daratumumab Shows Remarkable Benefit in Relapsed or Refractory Multiple Myeloma ...

Daratumumab is a fully human monoclonal antibody that binds to a novel target on myeloma cells.

Read more

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic...

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more